NASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $30.75 +0.07 (+0.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$30.31▼$31.4450-Day Range$25.77▼$30.7552-Week Range$21.99▼$35.44Volume353,448 shsAverage Volume474,228 shsMarket Capitalization$1.69 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Supernus Pharmaceuticals alerts: Email Address Supernus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.3% Upside$41.00 Price TargetShort InterestBearish11.99% of Float Sold ShortDividend StrengthN/ASustainability-2.35Upright™ Environmental ScoreNews Sentiment0.97Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth26.72%From $1.31 to $1.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector219th out of 936 stocksPharmaceutical Preparations Industry93rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSupernus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.99% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently increased by 3.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSupernus Pharmaceuticals has received a 58.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topiramate", "Safinamide", "Oxcarbazepine", and "Amantadine" products. See details.Environmental SustainabilityThe Environmental Impact score for Supernus Pharmaceuticals is -2.35. Previous Next 3.3 News and Social Media Coverage News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Supernus Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.76% of the stock of Supernus Pharmaceuticals is held by insiders.Read more about Supernus Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 26.72% in the coming year, from $1.31 to $1.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is -106.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is -106.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Supernus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Read More SUPN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SUPN Stock News HeadlinesJuly 23, 2024 | globenewswire.comSupernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024July 19, 2024 | investorplace.comIf You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 NamesJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 2, 2024 | seekingalpha.comSupernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD StandoutMay 30, 2024 | globenewswire.comSupernus Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 24, 2024 | finanznachrichten.deSupernus Pharmaceuticals, Inc.: Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in EpilepsyMay 24, 2024 | finance.yahoo.comDo Options Traders Know Something About Supernus (SUPN) Stock We Don't?May 23, 2024 | globenewswire.comSupernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in EpilepsyJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNMay 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)May 10, 2024 | finance.yahoo.comSupernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...May 9, 2024 | globenewswire.comSupernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comSupernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | investorplace.comSUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comSupernus Announces First Quarter 2024 Financial ResultsSee More Headlines Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CUSIP86845910 CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees652Year FoundedN/APrice Target and Rating Average Stock Price Target$41.00 High Stock Price Target$41.00 Low Stock Price Target$41.00 Potential Upside/Downside+33.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E Ratio23.47 P/E GrowthN/ANet Income$1.32 million Net Margins-2.60% Pretax Margin-1.01% Return on Equity-1.68% Return on Assets-1.20% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.49 Sales & Book Value Annual Sales$607.52 million Price / Sales2.78 Cash Flow$1.60 per share Price / Cash Flow19.21 Book Value$16.87 per share Price / Book1.82Miscellaneous Outstanding Shares54,970,000Free Float50,158,000Market Cap$1.69 billion OptionableOptionable Beta0.90 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jack A. Khattar (Age 63)Founder, President, CEO, Secretary & Director Comp: $1.63MMr. Timothy C. Dec (Age 65)Senior VP & CFO Comp: $635.43kDr. Padmanabh P. Bhatt Ph.D. (Age 67)Chief Scientific Officer & Senior VP of Intellectual Property Comp: $594.14kMr. Frank Mottola (Age 52)Senior Vice President of Quality, GMP Operations & Information Technology Comp: $490.87kDr. Jonathan Rubin M.D. (Age 63)MBA, Senior VP of Research & Development and Chief Medical Officer Comp: $594.65kMr. Kevin T. Anderson (Age 62)Compliance Officer Dr. Todd Horich M.B.A.Ph.D., Senior Vice President of Marketing & Market AccessMr. Taylor RaifordSenior Vice President of SalesDr. Bryan A. Roecklein Ph.D.Senior Vice President of Corporate DevelopmentMs. Tami T. Martin Esq. (Age 69)R.N., Senior Vice President of Regulatory Affairs Comp: $508.5kMore ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAOcular TherapeutixNASDAQ:OCULArcutis BiotherapeuticsNASDAQ:ARQTInnovivaNASDAQ:INVAORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,427 shares on 7/26/2024Ownership: 0.774%Allspring Global Investments Holdings LLCSold 1,930 shares on 7/26/2024Ownership: 0.063%Legato Capital Management LLCSold 5,933 shares on 7/26/2024Ownership: 0.039%Louisiana State Employees Retirement SystemBought 600 shares on 7/24/2024Ownership: 0.050%Nisa Investment Advisors LLCSold 388 shares on 7/20/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $28.94 at the start of the year. Since then, SUPN stock has increased by 6.3% and is now trading at $30.75. View the best growth stocks for 2024 here. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by $0.39. The firm's revenue for the quarter was down 1.8% compared to the same quarter last year. What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO? 20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees. Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.77%), Hennion & Walsh Asset Management Inc. (0.08%), Allspring Global Investments Holdings LLC (0.06%) and Louisiana State Employees Retirement System (0.05%). Insiders that own company stock include Tami Tillotson Martin, Frederick M Hudson, Padmanabh P Bhatt and Frank Mottola. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE) and GW Pharmaceuticals (GWPH). This page (NASDAQ:SUPN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
